+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

ObsEva SA (OBSN) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 49 Pages
  • August 2023
  • GlobalData
  • ID: 4395087
ObsEva SA (OBSN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ObsEva SA (ObsEva) is a clinical-stage biopharmaceutical company that develops and commercializes drugs for women's reproductive health and pregnancy. The company's product portfolio comprises pipeline products for controlling preterm labor by reducing inflammation, decreasing uterine contractions, and preventing cervical changes and membrane ruptures; for the treatment of pain in association with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women and to decrease contractions, improve uterine blood flow and enhance the receptivity of the endometrium to the embryo implantation. ObsEva is headquartered in Geneva, Switzerland.

ObsEva SA Key Recent Developments

  • May 02, 2023: ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer
  • Apr 28, 2023: ObsEva Annual Report 2022
  • Mar 31, 2023: ObsEva Files Year End 2022 Financial Statements
  • Mar 15, 2023: ObsEva announces progress towards its plans to consolidate operations in Switzerland: Delisting of OBSV from the Nasdaq Stock market effective March 23, 2023

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • ObsEva SA - Key Facts
  • ObsEva SA - Key Employees
  • ObsEva SA - Key Employee Biographies
  • ObsEva SA - Major Products and Services
  • ObsEva SA - History
  • ObsEva SA - Company Statement
  • ObsEva SA - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • ObsEva SA - Business Description
  • ObsEva SA - Corporate Strategy
  • ObsEva SA - SWOT Analysis
  • SWOT Analysis - Overview
  • ObsEva SA - Strengths
  • ObsEva SA - Weaknesses
  • ObsEva SA - Opportunities
  • ObsEva SA - Threats
  • ObsEva SA - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • ObsEva SA, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • ObsEva SA, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • ObsEva SA, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 02, 2023: ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer
  • Apr 28, 2023: ObsEva Annual Report 2022
  • Mar 31, 2023: ObsEva Files Year End 2022 Financial Statements
  • Mar 15, 2023: ObsEva announces progress towards its plans to consolidate operations in Switzerland: Delisting of OBSV from the Nasdaq Stock market effective March 23, 2023
  • Mar 13, 2023: ObsEva announces update towards its strategic reorganization to consolidate operations in Switzerland
  • Feb 24, 2023: ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
  • Dec 01, 2022: ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update
  • Oct 26, 2022: ObsEva announces progress on cost reduction initiatives and stay of Moratorium proceedings
  • Sep 13, 2022: ObsEva announces progress on restructuring initiatives
  • Aug 17, 2022: ObsEva Files Second Quarter 2022 Financial Statements
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • ObsEva SA, Key Facts
  • ObsEva SA, Key Employees
  • ObsEva SA, Key Employee Biographies
  • ObsEva SA, Major Products and Services
  • ObsEva SA, History
  • ObsEva SA, Subsidiaries
  • ObsEva SA, Key Competitors
  • ObsEva SA, Ratios based on current share price
  • ObsEva SA, Annual Ratios
  • ObsEva SA, Interim Ratios
  • ObsEva SA, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • ObsEva SA, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • ObsEva SA, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • ObsEva SA, Performance Chart (2018 - 2022)
  • ObsEva SA, Ratio Charts
  • ObsEva SA, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • ObsEva SA, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Ferring Holding SA
  • Myovant Sciences Inc
  • Stragen Pharma SA